Anmeldung erfolgt in Kürze...
Details werden geladen...
Most powerful obesity drug yet: People lost up to 25% of weight in trial - Ars Technica
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
Ähnliche Seiten
The Disney protests were a wake-up call about the risks of streaming mergers - Ars Technica
https://arstechnica.com/gadgets/2026/09/what-the-disney-protests-over-kimmel-taught-us-about-streaming-mergers/Discord gives more advertisers more tools to target its users - Ars Technica
https://arstechnica.com/gadgets/2026/09/discord-gives-advertisers-more-tools-to-target-its-users/
expert reaction to trial of new amylin-based weight-loss drug petrelintide, noting fewer side effects than GLP-1-based drugs | Science Media Centre
https://www.sciencemediacentre.org/expert-reaction-to-trial-of-new-amylin-based-weight-loss-drug-petrelintide-noting-fewer-side-effects-than-glp-1-based-drugs/
Breakthrough weight-loss drug helps diabetes patients lose a quarter of their body weight | The Independent
https://www.independent.co.uk/news/science/retatrutide-weight-loss-drug-type-2-diabetes-glp1p-b3058848.htmlFresh hope for diabetics as new weight loss drug helps them shed a quarter of their bodyweight | The Independent
https://www.independent.co.uk/news/science/type-2-diabetes-glp1-drugs-retatrutide-weight-loss-b3058491.html